PCVX stock forecast, quote, news & analysis
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases... Show more
Vaxcyte (PCVX) Stock Analysis: Waiting Game Intensifies Ahead of Pivotal OPUS-1 Phase 3 Readout
Key Takeaways
- Vaxcyte shares declined approximately 5.4% over the last 30 days, settling near $54.60 as of July 28, 2026, reflecting a broader consolidation phase for the clinical-stage vaccine developer.
- The company holds approximately $2.74 billion in cash and equivalents as of March 31, 2026, following a $632.5 million equity offering in February, providing a robust runway through multiple upcoming clinical catalysts.
- All three OPUS Phase 3 adult trials for lead candidate VAX-31 are fully enrolled, with topline data from the pivotal OPUS-1 noninferiority study expected in the fourth quarter of 2026.
- The VAX-A1 Phase 1 study for Group A Strep prevention was initiated in mid-2026, marking the expansion of Vaxcyte's pipeline beyond its pneumococcal conjugate vaccine franchise.
- Analyst consensus stands at Hold with an average price target of $86, alongside recent insider sales executed under pre-arranged 10b5-1 trading plans that contributed to mixed near-term sentiment.
Current Market Snapshot
Vaxcyte (PCVX) has traded within a relatively contained range over the past month, with the stock drifting from roughly $57.72 on June 29 to $54.60 as of the close on July 28, 2026 — a decline of about 5.4%. The pullback comes amid a quiet period for company-specific news flow, with no major data readouts or regulatory updates during the window. Trading volumes have remained moderate, and the stock continues to hover between its 50-day simple moving average of approximately $52.71 and its 200-day moving average near $54.71. Broader biotech sector sentiment has been mixed, and Vaxcyte's beta of 1.22 indicates modest sensitivity to overall market swings. Institutional ownership remains exceptionally high at approximately 96.78%, underscoring deep-rooted institutional conviction despite the stock's near-term drift.
Vaxcyte (PCVX) Business Overview and Competitive Position
Vaxcyte, Inc. is a clinical-stage vaccine innovation company headquartered in San Carlos, California, focused on engineering high-fidelity vaccines to prevent serious bacterial diseases. The company's lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) — the broadest-spectrum PCV candidate in the clinic — designed to protect against invasive pneumococcal disease (IPD) and pneumonia in both adults and infants. VAX-31 is being evaluated in a comprehensive Phase 3 adult program (OPUS-1, OPUS-2, OPUS-3) and a Phase 2 infant dose-finding study. Vaxcyte's proprietary cell-free protein synthesis platform, XpressCF, licensed from Sutro Biopharma (STRO), differentiates its manufacturing approach from conventional cell-based methods. The company also recently advanced VAX-A1, a vaccine candidate targeting Group A Streptococcus, into a Phase 1 clinical study, while earlier-stage programs include VAX-24 and VAX-GI for Shigella. The global PCV market, currently valued at approximately $8 billion, is projected to reach $12–13 billion over the next five to ten years, positioning Vaxcyte in a large and growing addressable market.
Recent Developments Driving PCVX
Several notable developments have shaped investor sentiment around PCVX in the past month. In early July, Vaxcyte announced participation in the BTIG Virtual Biotechnology Conference and the Leerink Partners Therapeutics Forum, maintaining visibility with the investment community ahead of critical data catalysts. On the analyst front, Zacks Research downgraded the stock from Hold to Strong Sell on July 14, while Weiss Ratings reiterated a Sell rating on July 6 — though six analysts maintain Buy ratings with a consensus target of $86. Insider transactions drew attention: CFO Andrew Guggenhime sold 10,000 shares at approximately $57.28 on July 6, and COO Jim Wassil sold 2,250 shares at roughly $56.33 on July 1, both under pre-existing 10b5-1 trading plans. Meanwhile, institutional activity remained dynamic, with Bank of New York Mellon increasing its stake by 5.6% in Q1 to approximately $27.6 million, while HSBC Holdings reduced its position by 84.6%. On the clinical front, the company disclosed at the Jefferies Global Healthcare Conference in early June that the first patient had been dosed in the VAX-A1 Phase 1 study, and management provided detailed expectations for the OPUS-1 readout, framing base-case and upside scenarios for investors.
Trending AI Robots
For traders looking to complement fundamental analysis with algorithm-driven strategies, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots actively trading thousands of tickers across multiple markets. Tickeron hosts hundreds of bots, each employing distinct strategies, timeframes, and performance metrics — yet only the top-performing and most relevant bots earn placement in this curated section. These bots range from short-term momentum plays to longer-duration swing and trend-following approaches, enabling users to explore automated strategies that align with different risk profiles and market conditions. Whether you are monitoring clinical-stage biotech names like PCVX or scanning broader sectors, the Trending AI Robots section provides a streamlined entry point into AI-assisted trading.
2026 Outlook and What Investors Should Watch
The remainder of 2026 holds several defining catalysts for Vaxcyte. The single most consequential event is the anticipated topline data readout from the OPUS-1 Phase 3 pivotal noninferiority trial in the fourth quarter. This study directly compares VAX-31 against both Prevnar 20 and Capvaxive, the current standard-of-care PCVs, and its outcome will heavily influence regulatory prospects and commercial positioning. Investors should also monitor progress on the VAX-A1 Phase 1 study, which represents Vaxcyte's first pipeline expansion beyond pneumococcal disease, as well as updates on manufacturing readiness at the Lonza-dedicated facility and the North Carolina fill-finish line. Macroeconomic factors — including interest rate policy, broader biotech sector fund flows, and risk appetite for pre-revenue clinical-stage companies — will continue to influence trading dynamics. With $2.74 billion in cash and no near-term financing risk, Vaxcyte is well capitalized heading into its most data-rich period, but the stock's trajectory through year-end will largely depend on whether OPUS-1 delivers a clean best-in-class dataset.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
PCVX in upward trend: 10-day moving average moved above 50-day moving average on June 30, 2026
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
PCVX moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
PCVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 250 cases where PCVX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.606) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology